Trial Profile
MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Mitoxantrone (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms 2MS1; MITOX-REBIF
- 28 Mar 2023 Status changed from active, no longer recruiting to completed.
- 29 Jan 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 20 Oct 2017 Status changed from recruiting to active, no longer recruiting.